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Exploring Mechanisms
of Graft Occlusion
Toward Improved Outcomes in
Coronary Artery Bypass Graft Surgery*
Robert F. Storey, DM
Sheffield, United Kingdom
The management and prevention of clinical events related
to atherothrombosis requires negotiation of the balance
between prevention of arterial thrombosis and maintenance
of hemostasis. Striking the right balance is a particular
challenge in patients undergoing coronary artery bypass
graft (CABG) surgery in view of the imperative for securing
hemostasis after surgery while avoiding potentially fatal
thrombotic graft occlusion. It is well recognized that oral
antiplatelet therapy is required in the long term to reduce
the risk of thrombotic graft occlusion. Aspirin has proven
efficacy in reducing the risk of graft occlusion (1) and has a
number of advantages in this regard: it reliably inhibits its
target, platelet cyclooxygenase (COX)-1, to a high level
with irreversibility of effect that provides a rationale for
once-daily dosing; its effects on hemostasis are limited, and
therefore, it usually can be safely administered within 24 h
after surgery or can be continued in the perioperative period;
and it is very cheap and therefore highly cost effective (2,3).
See page 1069
However, a major limitation of aspirin is that COX-1 has a
restricted role in platelet activation (Fig. 1), so that platelet
reactivity can remain high even with complete inhibition of
this enzyme (4). Consequently, it may lack efficacy under
circumstances where greater inhibition of platelet function
is required because of adverse local blood flow rheology or
highly thrombogenic vessel wall or systemic factors. Rarely,
aspirin fails to inhibit platelet COX-1 effectively, with
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The Medicines Company.principle factors being poor compliance, adverse interaction
with nonsteroidal anti-inflammatory drugs, increased plate-
let turnover (making once-daily dosing suboptimal), and
possibly platelet COX-2 expression. In this issue of the
Journal, Gluckman et al. (5) demonstrate how reliably
aspirin inhibits COX-1 in patients undergoing CABG
surgery, with few patients exhibiting poor inhibition partic-
ularly during chronic administration. Despite this, platelet
reactivity remains high in some patients. Higher levels of
shear-induced platelet aggregation assessed by the Platelet
Function Analyzer-100 collagen-adenosine diphosphate
cartridge assay (Siemens Healthcare Diagnostics, Newark,
Delaware), which is insensitive to COX-1 inhibition, are
shown to be associated with increased incidence of graft
occlusion. Because there is a rational basis for expecting
high platelet reactivity to increase the risk of graft occlusion,
this study provides a strong rationale for investigating
alternative or supplementary targets for antithrombotic
therapy beyond COX-1 for patients at higher risk of graft
occlusion resulting from either rheological factors (small-
diameter grafted vessel) or prothrombotic systemic factors,
including high platelet reactivity. Ticagrelor, an oral revers-
ibly binding inhibitor of the platelet P2Y12 receptor,
achieved greater and more consistent inhibition of platelet
aggregation in acute coronary syndrome patients enrolled in
the PLATO (Platelet Inhibition and Patient Outcomes)
study compared with clopidogrel (6) and was associated
with lower mortality in patients undergoing CABG surgery
in this study (7). These findings indicate the need for
further studies of P2Y12 inhibition for maintaining graft
atency. Protease-activated receptor (PAR)-1, a thrombin
eceptor present on platelets and other cells including vascular
mooth muscle cells, is another promising target because
nhibition has a significant antithrombotic effect, but little
ffect on hemostasis (8), potentially allowing therapy to be
aintained throughout the operative period. Two ongoing
hase 3 placebo-controlled studies of vorapaxar, a PAR-1
ntagonist, in patients with acute coronary syndromes or stable
therosclerotic disease should provide some information on the
fficacy and safety of this therapy in patients undergoing
ABG surgery.
Another finding in this study is that increased urinary
hromboxane B2 excretion at 6 months after surgery is associ-
ted with a higher incidence of graft occlusion at this time
oint. Although it is possible that the graft occlusion itself is
he cause of greater thromboxane A2 production through
ctivation of leukocytes and other cells in the thrombosed graft
nd other diseased grafts, the alternative hypothesis that
hromboxane A2 is linked to the causation of graft occlusion is
intriguing. This raises many questions about the role that
inflammatory processes, including induction of COX-2, play
in the pathogenesis of graft occlusion. The adverse cardiovas-
cular consequences of inhibiting COX-2 after CABG surgery
discourage specific targeting of this enzyme in CABG patients
(9), but encourage consideration of related targets that will not
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cells, an important factor in suppressing the reactivity of
circulating platelets. Inflammation increases the levels of coag-
ulation factors and vonWillebrand factor, as well as potentially
increasing platelet reactivity through increased platelet turn-
over; so, targeting appropriate signaling cascades involved in
inflammation could provide a unified approach to the problem
of graft occlusion. Balanced against this approach is the need to
allow adequate wound healing and to avoidwound infections after
surgery, which may be compromised by some anti-inflammatory
therapies and could justify delayed initiation of therapy.
It is notable that a medical history of diabetes mellitus was not
associated with early graft occlusion in this study, consistent with
the results of previous studies. Diabetes mellitus is associated with
a tendency toward higher platelet reactivity, higher levels of
procoagulant factors, greater systemic inflammation, and reduced
efficacy of aspirin (10,11), and consequently some signal of
increased graft failure in diabetic individualsmay be expected. The
lack of such a signal to date suggests a complexity to the
pathobiology of graft disease or perhaps a beneficial effect of
hypoglycemic medication. Further prospective studies of even
greater size and complexity are required to examine further the
influences of patient demographics and comorbidity, medication,
prothrombotic factors, and inflammation on graft failure.
In conclusion, the interrelationships between platelets, in-
Figure 1 Platelet Activation and Inhibition Mechanisms
Numerous platelet surface receptors mediate platelet activation by soluble agonis
adenosine triphosphate (ATP), and adenosine diphosphate (ADP), and by collagen.
of these agonists. ADP binds to 2 receptors, of which the P2Y12 receptor plays a
glycoprotein IIb/IIIa (integrin IIb3). Platelet activation not only leads to platelet a
through procoagulant changes in the surface membrane supporting thrombin gene
produce nitric oxide (NO) and prostacyclin (PGI2), which reduce platelet reactivity. Plate
GPVI  glycoprotein VI; PAR  protease-activated receptor; PDGF  platelet-derived g
ligand; TG  thromboglobulin; TGF  transforming growth factor; vWF  von Willebranflammation, and vascular disease weave a complex web. Futurestudies in patients undergoing CABG surgery should test more
effective antiplatelet strategies than COX-1 inhibition and
should identify promising targets for prevention of the vein
graft disease that may culminate in occlusion.
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